Phathom Pharmaceuticals
PHAT | NASDAQ
$5.88
-$0.18 (-2.97%)
At close: Nov 16, 2026, 4:00 PM ET
$5.88
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Phathom Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Steven L. Basta | Chief Executive Officer, President & Director |
| Anne Marie Cook | Chief Legal Officer & Corporate Secretary |
| Bill Aprea | Senior Vice President, Chief Compliance Officer & Deputy Chief Legal Officer |
| Paul Cocja | Chief People Officer |
| Azmi Nabulsi | Co-Founder |
| David A. Socks | Co-Founder |
| Eric Sciorilli | Director of Business Development & Investor Relations |
| Jonathan Bentley | Senior Vice President and Head of Sales, Operations & Training |
| Nancy R. Phelan | Senior Vice President of Marketing & Analytics |
| Robert Breedlove | Vice President of Finance & Principal Accounting Officer |
| Sanjeev Narula | Chief Financial & Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 26, 2026 | 8-K | Current Report |
| Oct 23, 2026 | 8-K | Current Report |
| Oct 08, 2026 | 4 | Filing |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 4 | Filing |
| Jul 30, 2026 | 10-Q | Quarterly Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 29, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Phathom Pharmaceuticals
| Country | United States |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 371 |
| CEO | Steven L. Basta |
Contact Details
100 Campus Drive Florham Park,
New Jersey 07932 United States
Stock Details
| Ticker Symbol | PHAT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001783183 |
| CUSIP Number | 71722W107 |
| ISIN Number | US71722W1071 |
| SIC Code | 2834 |
Recent News
- 7 months ago / globenewswire.comPhathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
- 9 months ago / globenewswire.comPhathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Add to Watchlist
Select watchlists to add or remove PHAT